Skip to content

Patiromer Efficacy across Kidney Function and Hyperkalemia Subgroups in Heart Failure and Reduced Ejection Fraction: A DIAMOND Post Hoc Analysis.

Oct 2026 · Kidney360 · 0 citations
Medicine

TL;DR

Patiromer reduced serum potassium across baseline kidney function and hyperkalemia subgroups, with greater effect in patients with reduced kidney function and baseline hyperkalemia, which suggest potential heterogeneity in potassium-lowering effects of patiromer across subgroups.

View source

Similar papers

Open access Oct 2026

Impact of renin-angiotensin system inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease

Renin-angiotensin system inhibitor (RASi) represents a cornerstone of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF). However, RASi is often underutilized in patients with advanced chronic kidney disease (CKD) due to concerns regarding hyperkalemia and worsening renal...

Y. Tamaki, H. Yaku, E. Yamamoto et al. · 0 citations
Open access Oct 2026

Renin-angiotensin system inhibition and survival in elderly HFrEF with CKD: a target trial emulation

Elderly patients with heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) are underrepresented in clinical trials. While ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) are cornerstone therapies for HFrEF, concerns about renal deterioration lead to underuse in patie...

P. Puiu, F. Ruschitzka, A. Flammer et al. · 0 citations
Oct 2026

Amlodipine and Nifedipine Associations with B-Type Natriuretic Peptide in Women with Hypertension and Heart Failure with Preserved Ejection Fraction.

BACKGROUND Calcium channel blockers (CCBs) are frequently prescribed to manage hypertension in patients with heart failure with preserved ejection fraction (HFpEF). However, whether individual dihydropyridine agents exert uniform class effects on myocardial wall stress remains unclear. METHODS This retrospective, sin...

E. Harada, T. Yamada, Y. Mizuno et al. · 0 citations
Nov 2026

Abstract 13852: Time in Normal-High Potassium Range and Cardiovascular Outcomes in Cardio-Kidney-Metabolic Syndrome: A FINE-HEART Analysis

Background: Serum potassium is a known prognostic marker in patients with heart failure (HF) and chronic kidney disease (CKD), with both hypo- and hyperkalemia associated with adverse outcomes. The POTCAST trial demonstrated that targeting a potassium range of 4.5-5.0 mmol/L may be optimal in patients at high risk f...

Henri Lu, B. Claggett, G. Filippatos et al. · 0 citations
Open access Oct 2026

Cardiorenal trade-off of sacubitril/valsartan in heart failure with reduced ejection fraction and advanced chronic kidney disease: a propensity-weighted multicentre analysis

Patients with heart failure with reduced ejection fraction (HFrEF) frequently have coexisting chronic kidney disease (CKD). Although angiotensin receptor–neprilysin inhibitors (ARNi) improve cardiovascular outcomes in HFrEF, evidence in advanced CKD is limited, particularly regarding progression to dialysis....

C. Hsu, T. N. K. N. Truong, Ching-Lin Hung · 0 citations
Open access Oct 2026

Finerenone and serum sodium in patients with heart failure and mildly reduced or preserved ejection fraction: an analysis of FINEARTS-HF

Older observational studies in cirrhosis and heart failure (HF) suggest that treatment with spironolactone is frequently associated with hyponatraemia, which is mechanistically plausible given the known actions of aldosterone. However, the effect of the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) f...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.